{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-056251","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.290920+00:00","generated_at":"2026-06-27T03:38:49.815749+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phase 3 roluperidone results published; primary endpoint missed significance in ITT","bullets":["Trial published in Schizophrenia Bulletin for roluperidone to treat negative symptoms in schizophrenia.","Primary endpoint NSFS missed statistical significance in ITT (p≤0.064) but hit in m-ITT (p≤0.044).","Secondary endpoint PSP total score statistically significant for 64 mg vs placebo (ITT p≤0.021).","FDA denied pre-NDA meeting in Nov 2021; Type C meeting scheduled; NDA submission planned H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-056251","json":"https://secwatch.observer/filing/0001193125-22-056251.json","markdown":"https://secwatch.observer/filing/0001193125-22-056251.md","text":"https://secwatch.observer/filing/0001193125-22-056251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312522056251/0001193125-22-056251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312522056251/d321129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:38:49.815749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}